# Management of Bladder Cancer Patients with Clinical Evidence of Lymph Node Invasion (cN+).

**Tumor:** Cáncer de vejiga músculo-invasivo
**Autores:** Ma&#x142;kiewicz B, Gurwin A, Karwacki J et al
**Revista:** Cancers (Basel) (2022)
**PMID:** 36358705 | **PMCID:** PMC9656528
**DOI:** [10.3390/cancers14215286](https://doi.org/10.3390/cancers14215286)
**Fuente:** PubMed Central (open access)

## Relevancia
Cáncer de vejiga músculo-invasivo (cN+/cN0) tras quimioterapia neoadyuvante basada en cisplatino o inmunoterapia (KEYNOTE-866, EV-302): tasas de ypN0, calidad de PLND y pronóstico. Similar al paradigma mamario: la respuesta ganglionar patológica es un marcador pronóstico clave y la PLND completa sigue siendo esencial incluso con downstaging.

## Abstract
The purpose of this review is to present the current knowledge about the diagnostic and treatment options for bladder cancer (BCa) patients with clinically positive lymph nodes (cN+). This review shows compaction of CT and MRI performance in preoperative prediction of lymph node invasion (LNI) in BCa patients, along with other diagnostic methods. Most scientific societies do not distinguish cN+ patients in their guidelines; recommendations concern muscle-invasive bladder cancer (MIBC) and differ between associations. The curative treatment that provides the best long-term survival in cN+ patients is a multimodal approach, with a combination of neoadjuvant chemotherapy (NAC) and radical cystectomy (RC) with extended pelvic lymph node dissection (ePLND). The role of adjuvant chemotherapy (AC) remains uncertain; however, emerging evidence indicates comparable outcomes to NAC. Therefore, in cN+ patients who have not received NAC, AC should be implemented. The response to ChT is a crucial prognostic factor for cN+ patients. Recent studies demonstrated the growing importance of immunotherapy, especially in ChT-ineligible patients. Moreover, immunotherapy can be suitable as adjuvant therapy in selected cases. In cN+ patients, the extended template of PLND should be utilized, with the total resected node count being less important than the template. This review is intended to draw special attention to cN+ BCa patients, as the oncological outcomes are significantly worse for this group.

## Acceso
Disponible en PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC9656528/

---
*Datos de PubMed. Citar: doi 10.3390/cancers14215286*
